PRIDE: A phase IIa, open-label, multicenter study of radiochemotherapy with isotoxic dose escalation and protective VEGF inhibition using bevacizumab in the treatment of patients with first diagnosis of IDH wild-type, MGMT unmethylated glioblastoma

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-514865-20-00

Acronym

PRIDE

Enrollment

146

Registered

2024-07-10

Start date

2024-04-10

Completion date

Unknown

Last updated

2025-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glioblastoma

Brief summary

Overall survival

Detailed description

Safety and tolerability of isotoxic dose escalation and bevacizumab, Progression-free survival after 6 months (PFS-6), Progression-free survival (PFS), Quality of life as determined by EORTC QLQ-C30 and the EORTC brain module QLQ-BN 20, Cognitive function as determined by MMSE and MOCA, Exploratory objective: validation of 4-miRNA signature-based risk subgroups in FFPE material and plasma samples

Interventions

DRUGAybintio 25 mg/ml concentrate for solution for infusion.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Overall survival	—

Secondary

Measure	Time frame
Safety and tolerability of isotoxic dose escalation and bevacizumab, Progression-free survival after 6 months (PFS-6), Progression-free survival (PFS), Quality of life as determined by EORTC QLQ-C30 and the EORTC brain module QLQ-BN 20, Cognitive function as determined by MMSE and MOCA, Exploratory objective: validation of 4-miRNA signature-based risk subgroups in FFPE material and plasma samples	—

Countries

Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026